Back
Johnson & Johnson agrees $5.5 billion talc settlement covering 99.75% of claims

Johnson & Johnson agrees $5.5 billion talc settlement covering 99.75% of claims

The proposed deal would cover roughly 76,000 ovarian cancer claims, requires 95% claimant approval and includes an initial payment of up to $3 billion in 2027, with later payments after 2028.

Fact Check
Multiple independent authoritative sources confirm the core claim. Reuters (Yahoo Finance syndication) explicitly states the $5.5 billion settlement covers about 69,000 federal cases plus related state cases, equal to 99.75% of remaining talc claims, resolving cases after J&J's failed bankruptcy efforts. The Levin Papantonio press release confirms at least $5.5 billion covering approximately 70,000 claimants in the federal MDL and state courts. WSJ corroborates the $5.5 billion figure. Every specific element of the claim—the dollar amount, the ~70,000 claimants, the 99.75% coverage, the federal MDL and related state cases, and the prior failed bankruptcy attempts—is directly supported.
    Reference: 123
Summary

Johnson & Johnson said it reached a potential $5.5 billion settlement to resolve ovarian cancer claims tied to its talc products, covering about 76,000 cases in federal multidistrict litigation and related state court proceedings. The agreement would take effect only if law firms representing at least 95% of claimants sign on, with an initial payout of as much as $3 billion in 2027 and any remaining balance to be distributed after 2028. Johnson & Johnson continues to deny the allegations, with Erik Haas, worldwide vice president of litigation, saying the company believes it would have prevailed in continued litigation and arguing the claims lack specific causation evidence. The proposal follows a July 22 court order requiring plaintiffs to show why roughly 69,000 claims should not be dismissed for failing to establish a specific link between ovarian cancer and Johnson & Johnson’s products. The company stopped selling talc-based baby powder in North America in 2020, extended the phaseout globally in 2023 and later spun off its consumer health division, Kenvue, in August 2023.

Terms & Concepts
  • multidistrict litigation: A legal procedure that groups similar lawsuits from different courts before one judge for coordinated pretrial handling.
  • specific causation: Evidence intended to show that a particular product or exposure caused an individual plaintiff’s injury or illness.
  • asbestos: A hazardous mineral fiber linked to serious diseases including mesothelioma and other cancers.